Imatinib Actavis Unió Europea - islandès - EMA (European Medicines Agency)

imatinib actavis

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , Áhrif imatinib á niðurstöðu beinmerg ígræðslu hefur ekki verið ákveðið. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. reynslu með imatinib í sjúklinga með stýrð útgjöld/mpd tengslum við pdgfr gene aftur fyrirkomulag er mjög takmarkað. Það eru ekki stjórnað rannsóknir sýna klínískum gagnast eða jókst að lifa fyrir þessum sjúkdómum.

Possia Unió Europea - islandès - EMA (European Medicines Agency)

possia

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - blóðþurrðandi lyf - possia, sam-gefið með asetýlsalisýlsýru (asa), er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga með bráð kransæðastíflu heilkennum (óstöðug hjartslætti, non-l-hæð kransæðastíflu [nstemi] eða l-hæð kransæðastíflu [st-hækkun]); þar á meðal sjúklinga tókst læknisfræðilega, og þeir sem er stjórnað með stungið kransæðastíflu afskipti (náist á ný) eða hjarta slagæð með því-að fara að græða (hjÁveituaÐgerÐ).

Methylphenidate Medical Valley Forðatafla 27 mg Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

methylphenidate medical valley forðatafla 27 mg

medical valley invest ab - methylphenidatum hýdróklóríð - forðatafla - 27 mg

Concerta Forðatafla 18 mg Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

concerta forðatafla 18 mg

janssen-cilag ab - methylphenidatum hýdróklóríð - forðatafla - 18 mg

Concerta Forðatafla 27 mg Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

concerta forðatafla 27 mg

janssen-cilag ab - methylphenidatum hýdróklóríð - forðatafla - 27 mg

Concerta Forðatafla 36 mg Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

concerta forðatafla 36 mg

janssen-cilag ab - methylphenidatum hýdróklóríð - forðatafla - 36 mg

Concerta Forðatafla 54 mg Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

concerta forðatafla 54 mg

janssen-cilag ab - methylphenidatum hýdróklóríð - forðatafla - 54 mg